Nucleo
The first Agentic platform for Oncology
Nucleo is active in the healthcare space based in Chippendale, New South Wales, AU, founded in 2008.
Profile
We help oncologists and radiologists extract insights from CT scans to support tumor characterization and treatment.
The hospitals we work with include Stanford Hospital, Cedars-Sinai, UCI Health, and Weill Cornell.
The company sits in the healthcare segment, where it competes on its core product or service.
Chippendale, New South Wales, AU is where the company is located.
Its current recorded stage is Fall 2025.
Its team size is recorded as 2 employees.
Directory analysis
Nucleo is an Australian healthcare company that offers an agentic platform to assist oncologists and radiologists in extracting actionable insights from CT scans for tumor characterization and treatment planning. The platform is deployed in leading U.S. hospitals such as Stanford, Cedars‑Sinai, UCI Health, and Weill Cornell. Founded in 2008, the company operates with a small team of two employees.
Positioning: Nucleo operates at the intersection of AI‑driven radiology and oncology, targeting high‑profile academic medical centers. Its early‑stage positioning suggests a focus on specialized diagnostic support within a competitive AI‑healthcare landscape.
Note: Nucleo is based in Chippendale, New South Wales, Australia.
Auto-generated directory analysis from public data · updated 8 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | Chippendale, New South Wales, AU |
| Country | AU |
| Founded | 2008 |
| Employees | 2 |
| Stage | Fall 2025 |
Website: nucleoresearch.com
Browse related
Create a free account